Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
SwainsonineCat. No. 3208 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (1S,2R,8R,8aR)-Octahydro-1,2,8-indolizinetriol |
Biological Activity
Inhibitor of α-mannosidase II which inhibits glycoprotein processing. Displays anticancer and immune modulatory properties.Technical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Tulsiani et al (1982) Swainsonine inhibits the biosynthesis of complex glycoproteins by inhibition of golgi mannosidase II. J.Biol.Chem. 257 7936. PMID: 6806288.
Olden et al (1991) The potential importance of swainsonine in therapy for cancers and immunology. Pharmacol.Ther. 50 285. PMID: 1754603.
Sun et al (2007) Inhibition of the growth of human gastric carcinoma in vivo and in vitro by swainsonine. Phytomedicine 14 353. PMID: 17097281.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Swainsonine, supplier, inhibitors, α-mannosidase, alpha-mannosidase, II, Glycosylases, Carbohydrate, Metabolism
Quick Order
Find multiple products by catalog number
New Product E-alerts
Sign up for email updates from Tocris
New Products in this Area
Fluorescent cytochrome P450 substrate
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.